Abstracts tagged "osteoclastogenesis and rheumatoid arthritis"

Abstract Number: 961 • 2017 ACR/ARHP Annual Meeting
Adalimumab Reduces CXCR4 Expression during Inflammatory Arthritis and in Fibroblast-like Synoviocytes and Osteoclasts Under Chronic TNF Exposure
Bohdan P. Harvey¹, Li Li¹, Mark Konrad¹, Heather Knight¹, Susan Westmoreland², Melanie Ruzek¹ and Zehra Kaymakcalan¹, ¹AbbVie Bioresearch Center, Worcester, MA, ²AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: The CXCL12/CXCR4 chemokine axis has been implicated in the pathogenesis of RA. The expression of this chemokine and receptor has been shown to be…
Abstract Number: 1320 • 2017 ACR/ARHP Annual Meeting
TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Ameliorates Inflammation and Bone Erosion in Murine Model for Rheumatoid Arthritis
Yohei Yoshiga¹, Fumihito Hosoi¹, Satoru Iguchi¹, Ryuusuke Kaneko², Yoshinori Nakachi¹, Daichi Akasaka², Kenji Tanaka², Kazuhiko Yonekura², Teruhiro Utsugi², Eiji Sasaki² and Yoshikazu Iwasawa², ¹TAIHO PHARMACEUTICAL CO., LTD., TSUKUBA, Japan, ²TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan
Background/Purpose: The erosions of bone and cartilage are a cardinal feature of rheumatoid arthritis (RA) and associated with disease severity and poor functional outcome. Although…
Abstract Number: 1510 • 2014 ACR/ARHP Annual Meeting
Blockade of TLR5 Ligation Is a Novel Strategy for RA Therapy
Seung-jae Kim¹, Zhenlong Chen¹, Abdul Essani², Michael Volin³, Suncica Volkov¹, William Swedler⁴, Shiva Arami², Nadera J. Sweiss⁵ and Shiva Shahrara¹, ¹Medicine/Rheumatology, University of Illinois at Chicago, Chicago, IL, ²University of Illinois at Chicago, Chicago, IL, ³Microbiology & Immunology, Midwestern University, Downers Grove, IL, ⁴Section of Rheumatology, University of Illinois at Chicago, Chicago, IL, ⁵internal medicine section of rheumatology, University of Illinois at Chicago, Chicago, IL
Background/Purpose: TLR5 expression is highly elevated in RA and CIA lining and sublining macrophages and endothelial cells compared to non-arthritic controls. Additionally, expression of TLR5…
Abstract Number: 39 • 2014 ACR/ARHP Annual Meeting
Human CD14⁺ Monocytes Stimulated with a Combination of TNFα and IL-6 Differentiate into Osteoclast-like Cells with Bone-Resorption Activity
Kazuhiro Yokota¹, Kojiro Sato², Yoshimi Aizaki², Yuji Akiyama² and Toshihide Mimura², ¹Department of Rheumatology & Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose Proinflammatory cytokines play an important role in bone destruction in rheumatoid arthritis (RA), as inferred by the efficacy of biologics. Previously, we reported that…
Abstract Number: 332 • 2012 ACR/ARHP Annual Meeting
Blockade of CTGF Restores Aberrant Ostoclastgenesis in Collagen Induced Arthritis (CIA) Mice Through Inhibition of Th-17 Differentiation
Kazuhisa Nozawa¹, Maki Fujishiro², Ayako Yamaguchi¹, Mikiko Kawasaki², Shouzou Ichinose², Mitsuaki Yanagida², Kazuhisa Iwabuchi², Keigo Ikeda³, Shinji Morimoto⁴, Megumi Morioka⁵, Yoshinari Takasaki⁶ and Iwao Sekigawa³, ¹Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan, ³Internal Medicine 2, Juntendo University Urayasu Hospital, Tomioka, Urayasu, Chiba, Japan, ⁴Juntendo University Urayasu Hospital, Tokyo, Japan, ⁵Nihon Nosan Corporation, Nihon Nosan Corporation, Kanagawa, Japan, ⁶Internal Medicine and Rheumatology,, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Our previous study demonstrated changes in the profiles of serum protein biomarkers in infliximab-treated rheumatoid arthritis (RA) patients using a novel approach to proteomic…
Abstract Number: 32 • 2012 ACR/ARHP Annual Meeting
Development of a Quantitative Model of Endotoxin-Induced Calvarial Bone Erosion Utilizing Micro-Computed Tomography and Pax-It Imaging Analysis Software
Diane Thome, Donald Souza, Aruna Behera, Jie Zheng, Jennifer Swantek and Gerald H. Nabozny, Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT
Background/Purpose: To facilitate an understanding of the biological factors involved in inflammation- mediated bone loss, in vitro systems and murine models of bone loss, such…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].